BiotechTube
Home/Pipeline/EMUNKITUG (HFB200301)

EMUNKITUG (HFB200301)

Immuno-Oncology

Phase 1Active

Key Facts

Indication
Immuno-Oncology
Phase
Phase 1
Status
Active
Company
HiFiBiO Therapeutics

About HiFiBiO Therapeutics

HiFiBiO Therapeutics, founded in 2017 and based in Cambridge, USA, is a private biotechnology company advancing a pipeline of immunotherapies in immuno-oncology and inflammatory/immunological diseases. Its core asset is the DIS® platform, a data-driven engine combining high-resolution single-cell analysis with computational biology to deconvolute disease biology and accelerate therapeutic development. The company has demonstrated strong translational capabilities, with multiple INDs cleared and programs in Phase 1 trials, supported by a broad network of over 12 strategic partnerships.

View full company profile

Therapeutic Areas

Immuno-OncologyInflammatory & Immunological Diseases

Other Immuno-Oncology Drugs

DrugCompanyPhase
PD-1/PD-L1 Inhibitor Binding Assay KitAurora BiolabsCommercial
CTLA-4/B7-1 Inhibitor Screening KitAurora BiolabsCommercial
OX40 & PD-1 AssayAurora BiolabsCommercial
HPK1 inhibitorAcelleraPre-clinical
SKP2-CKS1 PPI InhibitorIktosHit-to-Lead
PD-1 Expression InhibitorBCN BiosciencesPreclinical
CCR8 ADCIntegral MolecularPreclinical
KB16AKBioDiscovery
NeoSight Neoantigen DetectionReproCELLResearch/Clinical
HFB200603HiFiBiO TherapeuticsPhase 1
Undisclosed Multispecific TherapeuticsModeX TherapeuticsPre-clinical
UndisclosedOnco3R TherapeuticsPreclinical